Replies to post #161314 on Biotech Values

[mcbio]

Esperion acquired other drugs that were in the old esperion pipeline.

the drug that was very difficult to make was apo milano and I believe that pfizer licensed that to the medicines company.

Esperion's Web site makes specific reference to ETC-1002 and notes it has completed five clinical trials. See: http://www.esperion.com/therapies/clinical-trials.php . Are you sure this is not the same drug that PFE had been working on? I do see a PR from the company makes reference to this drug being orally-available and I don't believe that was the case with the prior drug that PFE was involved with.

[biocqr]

ESPR - Esperion upcoming catalysts...

In the first half of September 2013, report top-line results from the ETC-1002-007 Phase 2a clinical study in approximately 52 patients with hypercholesterolemia taking a 10 mg dose of atorvastatin.

In October 2013, initiate the ETC-1002-008 Phase 2b clinical study in approximately 322 patients with hypercholesterolemia and either a history of statin intolerance or a history of statin tolerance. The goal of this study is to demonstrate comparable tolerability and superior efficacy to ezetimibe for the treatment of patients with elevated LDL-C levels and intolerance to two or more statins due to muscle-related adverse events.

Later in 2013, present full results of the ETC-1002-006 Phase 2a clinical study in patients with hypercholesterolemia and a history of statin intolerance at a major scientific meeting.

http://finance.yahoo.com/news/esperion-therapeutics-reports-second-quarter-121900892.html